Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05981703 · ClinicalTrials.gov registry record · Phase 1
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
A Phase 1 study of Solid Tumor and Advanced Solid Tumor, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 217
- Enrollment target
- 20
- Study locations
NCT05981703 is a Phase 1 study of Solid Tumor and Advanced Solid Tumor that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 217 participants, roughly in line with the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target. The trial reports 20 study locations across 16 states.
The verdict
NCT05981703, a Phase 1 study of Solid Tumor and Advanced Solid Tumor, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 217 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.
Conditions Studied
Interventions
- DRUG Tislelizumab
- DRUG Chemotherapy
- DRUG BGB-26808
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- University of Southern Californianorris Comprehensive - Los Angeles
New South Wales
- Southside Cancer Care - Miranda
- Macquarie University - North Ryde
Hubei
- Hubei Cancer Hospital - Wuhan
- Tongji Hospital,Tongji Medical College of Hustsino French New City Branch - Wuhan
Shandong
- Jining No1 Peoples Hospital West Branch - Jining
- Yantai Yuhuangding Hospital - Yantai
Connecticut
- Yale University, Yale Cancer Center - New Haven
Florida
- Sylvester Cancer Center, University of Miami - Miami
New Jersey
- John Theurer Cancer Center Hackensack University Medical Center - Hackensack
New York
- Icahn School of Medicine At Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2023-09-21 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05981703
The ClinicalTrials.gov registry entry for NCT05981703 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target. The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Tislelizumab is the first listed.
NCT05981703 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, New South Wales, Hubei.
Frequently Asked Questions
What is clinical trial NCT05981703 about?
NCT05981703 is a clinical study titled "A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors". This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.
What is the current status of trial NCT05981703?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 217 participants. The study started on 2023-09-21. Estimated completion is 2027-09-30.
What conditions does trial NCT05981703 study?
This clinical trial studies the following conditions: Solid Tumor, Advanced Solid Tumor.
What interventions are being tested in trial NCT05981703?
The interventions under investigation include: Tislelizumab (DRUG), Chemotherapy (DRUG), BGB-26808 (DRUG).
Who is sponsoring clinical trial NCT05981703?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05981703 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.